Koninklijke Philips N.V. Peer Comparison
Metric | Value | Ranking | ||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Market Cap | $26.3 Billion | 6/20 | ABT $226.3B |
BSX $155.9B |
SYK $147.0B |
MDT $117.1B |
EW $44.7B |
PHG $26.3B |
STE $21.5B |
ZBH $19.7B |
PODD $19.6B |
GMED $11.4B |
BIO $8.8B |
GKOS $7.9B |
BRKR $7.8B |
INSP $5.6B |
NARI $4.7B |
ITGR $4.6B |
NVCR $2.3B |
NUVA $2.1B |
CNMD $1.9B |
ZIMV $361.3M |
Gross Margin | 46% | 17/20 | PODD 100% |
ZIMV 95% |
NARI 87% |
INSP 84% |
EW 81% |
GKOS 77% |
NVCR 77% |
NUVA 72% |
BSX 69% |
MDT 65% |
SYK 65% |
GMED 57% |
CNMD 57% |
ABT 56% |
BIO 55% |
BRKR 47% |
PHG 46% |
STE 44% |
ITGR 16% |
ZBH 0% |
Profit Margin | 4% | 14/20 | EW 100% |
BIO 100% |
PODD 21% |
ABT 15% |
MDT 15% |
CNMD 15% |
BSX 11% |
STE 11% |
INSP 9% |
SYK 8% |
GMED 8% |
BRKR 5% |
ITGR 5% |
PHG 4% |
NUVA 2% |
ZBH 0% |
ZIMV -4% |
NARI -12% |
NVCR -20% |
GKOS -22% |
EBITDA margin | 8% | 10/20 | BIO 214% |
EW 30% |
PODD 24% |
CNMD 21% |
NUVA 19% |
BSX 18% |
ABT 18% |
STE 17% |
SYK 9% |
PHG 8% |
GMED 8% |
ITGR 8% |
INSP 7% |
MDT 0% |
ZIMV -3% |
NARI -5% |
BRKR -9% |
NVCR -21% |
GKOS -26% |
ZBH -100% |
Quarterly Revenue | $4.8 Billion | 4/20 | ABT $10.6B |
MDT $8.4B |
SYK $6.4B |
PHG $4.8B |
BSX $4.2B |
EW $1.4B |
STE $1.3B |
BRKR $864.4M |
ITGR $746.3M |
BIO $649.7M |
GMED $625.7M |
PODD $372.6M |
NUVA $317.8M |
CNMD $316.7M |
INSP $203.2M |
NVCR $155.1M |
NARI $153.4M |
ZIMV $103.2M |
GKOS $96.7M |
ZBH $0 |
Quarterly Earnings | $198.9 Million | 7/20 | EW $3.1B |
ABT $1.6B |
MDT $1.3B |
BIO $653.2M |
SYK $546.0M |
BSX $468.0M |
PHG $198.9M |
STE $150.0M |
PODD $77.5M |
GMED $51.8M |
CNMD $49.0M |
BRKR $40.9M |
ITGR $35.4M |
INSP $18.5M |
NUVA $7.4M |
ZBH -$0 |
ZIMV -$4.4M |
NARI -$18.4M |
GKOS -$21.4M |
NVCR -$30.6M |
Quarterly Free Cash Flow | $301.1 Million | 3/20 | MDT $554.0M |
EW $319.9M |
PHG $301.1M |
BIO $246.7M |
GMED $161.7M |
STE $148.8M |
ITGR $131.8M |
PODD $76.1M |
CNMD $47.8M |
INSP $44.3M |
BRKR $5.8M |
ZIMV $4.6M |
ABT -$0 |
NVCR -$307,000 |
NUVA -$495,000 |
NARI -$995,000 |
GKOS -$11.0M |
BSX -$1.1T |
ZBH -$0 |
SYK -$0 |
Trailing 4 Quarters Revenue | $19.8 Billion | 5/20 | BIO $2.7T |
ABT $41.2B |
MDT $33.0B |
SYK $22.6B |
PHG $19.8B |
BSX $15.9B |
EW $5.9B |
ZBH $5.7B |
STE $5.4B |
BRKR $3.2B |
GMED $2.5B |
ITGR $2.0B |
PODD $1.8B |
CNMD $1.3B |
NUVA $1.2B |
INSP $755.6M |
NVCR $577.7M |
NARI $574.5M |
ZIMV $451.3M |
GKOS $360.3M |
Trailing 4 Quarters Earnings | -$515.4 Million | 19/20 | ABT $10.6B |
MDT $8.4B |
SYK $6.4B |
PHG $4.8B |
BSX $4.2B |
EW $1.4B |
STE $1.3B |
BRKR $864.4M |
ITGR $746.3M |
BIO $649.7M |
GMED $625.7M |
PODD $372.6M |
NUVA $317.8M |
CNMD $316.7M |
INSP $203.2M |
NVCR $155.1M |
NARI $153.4M |
ZIMV $103.2M |
GKOS $96.7M |
ZBH -$0 |
Quarterly Earnings Growth | 106% | 7/20 | GMED 5094% |
NUVA 925% |
EW 698% |
BIO 515% |
INSP 317% |
CNMD 209% |
PHG 106% |
PODD 49% |
MDT 40% |
NVCR 38% |
GKOS 30% |
STE 30% |
ITGR 30% |
ABT 15% |
ZIMV 13% |
ZBH 0% |
BSX -7% |
SYK -52% |
BRKR -54% |
NARI -681% |
Annual Earnings Growth | -254% | 18/20 | EW 218% |
PODD 215% |
INSP 174% |
CNMD 131% |
ZIMV 58% |
BSX 36% |
ZBH 36% |
NVCR 32% |
MDT 31% |
BRKR 18% |
ITGR 15% |
ABT 4% |
SYK -7% |
STE -11% |
GKOS -16% |
GMED -47% |
NUVA -50% |
PHG -254% |
NARI -934% |
BIO -18757% |
Quarterly Revenue Growth | -2% | 16/20 | GMED 63% |
INSP 33% |
GKOS 24% |
NVCR 22% |
NARI 21% |
BSX 19% |
BRKR 16% |
SYK 11% |
ITGR 6% |
ABT 5% |
MDT 5% |
CNMD 4% |
BIO 3% |
NUVA 2% |
STE -1% |
PHG -2% |
EW -9% |
PODD -14% |
ZIMV -49% |
ZBH -100% |
Annual Revenue Growth | 1% | 18/20 | BIO 99740% |
GMED 97% |
INSP 25% |
NARI 19% |
BRKR 16% |
NVCR 14% |
GKOS 13% |
PODD 12% |
BSX 11% |
SYK 10% |
MDT 6% |
ITGR 6% |
ZBH 4% |
NUVA 4% |
STE 4% |
ABT 3% |
CNMD 2% |
PHG 1% |
EW -3% |
ZIMV -49% |
Cash On Hand | $2.0 Billion | 4/20 | EW $3.7B |
SYK $3.7B |
BSX $2.5B |
PHG $2.0B |
MDT $1.4B |
PODD $902.6M |
GMED $622.8M |
ZBH $525.5M |
BIO $410.4M |
STE $172.2M |
BRKR $148.1M |
INSP $147.5M |
GKOS $100.1M |
NUVA $80.7M |
ZIMV $66.8M |
NARI $41.1M |
CNMD $38.5M |
ITGR $35.6M |
ABT -$0 |
NVCR -$0 |
Short Term Debt | $0 | 18/20 | SYK $12.2B |
MDT $3.7B |
BSX $1.7B |
ZBH $863.0M |
NUVA $360.8M |
NVCR $86.4M |
STE $80.0M |
PODD $42.0M |
BRKR $32.8M |
EW $24.2M |
ITGR $13.9M |
GMED $11.0M |
ZIMV $4.4M |
NARI $1.6M |
BIO $1.3M |
CNMD $717,000 |
INSP $109,000 |
PHG -$0 |
ABT -$0 |
GKOS -$0 |
Long Term Debt | $0 | 17/20 | MDT $24.6B |
BSX $9.2B |
ZBH $5.3B |
STE $2.3B |
BRKR $2.3B |
PODD $1.4B |
BIO $1.2B |
ITGR $1.2B |
CNMD $940.1M |
EW $682.5M |
NUVA $545.4M |
GMED $523.5M |
ZIMV $220.3M |
GKOS $157.1M |
NARI $31.1M |
INSP $25.2M |
PHG $0 |
ABT $0 |
SYK $0 |
NVCR $0 |
PE | -1.00 | 15/20 | INSP 169.57 |
GMED 125.00 |
BSX 87.14 |
NUVA 73.28 |
STE 49.51 |
SYK 49.12 |
PODD 46.59 |
ITGR 40.57 |
ABT 39.25 |
ZBH 29.66 |
MDT 27.31 |
BRKR 25.68 |
CNMD 14.66 |
EW 10.75 |
PHG -1.00 |
GKOS -1.00 |
NVCR -1.00 |
BIO -1.00 |
NARI -1.00 |
ZIMV -1.00 |
PS | 1.21 | 18/20 | GKOS 21.98 |
PODD 10.82 |
BSX 9.80 |
NARI 8.15 |
EW 7.61 |
INSP 7.42 |
SYK 6.51 |
ABT 5.49 |
GMED 4.62 |
NVCR 4.00 |
STE 3.97 |
MDT 3.55 |
ZBH 3.48 |
BRKR 2.42 |
ITGR 2.29 |
NUVA 1.70 |
CNMD 1.50 |
PHG 1.21 |
ZIMV 0.80 |
BIO 0.00 |
PB | 0.00 | 18/20 | PODD 17.54 |
GKOS 11.85 |
NARI 10.77 |
INSP 8.05 |
BSX 7.44 |
EW 4.65 |
BRKR 4.25 |
SYK 3.42 |
STE 3.26 |
ITGR 2.84 |
GMED 2.81 |
MDT 2.40 |
NUVA 2.34 |
CNMD 2.07 |
ZBH 1.37 |
BIO 1.17 |
ZIMV 0.89 |
PHG 0.00 |
ABT 0.00 |
NVCR 0.00 |
PC | 13.26 | 16/20 | ITGR 129.50 |
STE 125.02 |
NARI 113.76 |
MDT 84.03 |
GKOS 79.09 |
BSX 62.30 |
BRKR 52.87 |
CNMD 50.19 |
SYK 40.25 |
INSP 37.99 |
ZBH 37.50 |
NUVA 25.83 |
PODD 21.72 |
BIO 21.35 |
GMED 18.37 |
PHG 13.26 |
EW 12.16 |
ZIMV 5.41 |
ABT -1.00 |
NVCR -1.00 |
Liabilities to Equity | 0.00 | 18/20 | NVCR 2.39 |
BRKR 2.34 |
PODD 1.71 |
CNMD 1.48 |
NUVA 1.34 |
ITGR 0.95 |
ZIMV 0.93 |
MDT 0.85 |
BSX 0.83 |
NARI 0.60 |
STE 0.55 |
ZBH 0.48 |
BIO 0.42 |
GKOS 0.39 |
EW 0.35 |
GMED 0.25 |
INSP 0.14 |
PHG 0.00 |
ABT 0.00 |
SYK 0.00 |
ROA | -1.00 | 17/20 | EW 32% | PODD 14% | SYK 7% | CNMD 6% | BSX 5% | MDT 5% | BRKR 5% | STE 4% | ITGR 4% | INSP 4% | ZBH 3% | GMED 2% | NUVA 1% | ZIMV -4% | NARI -11% | GKOS -16% | PHG -100% | ABT -100% | NVCR -100% | BIO -6012% |
ROE | -0.04 | 14/20 | EW 44% |
PODD 38% |
BRKR 17% |
CNMD 14% |
BSX 9% |
MDT 9% |
SYK 7% |
STE 7% |
ITGR 7% |
ZBH 5% |
INSP 5% |
NUVA 3% |
GMED 2% |
PHG -4% |
ZIMV -8% |
NARI -18% |
GKOS -22% |
NVCR -42% |
ABT -100% |
BIO -8513% |
Current Ratio | -1.00 | 18/20 | INSP 7.99 |
GMED 5.00 |
EW 3.86 |
GKOS 3.59 |
BIO 3.40 |
ZBH 3.08 |
STE 2.82 |
NARI 2.66 |
BSX 2.22 |
MDT 2.18 |
ZIMV 2.08 |
ITGR 2.05 |
NUVA 1.75 |
CNMD 1.67 |
PODD 1.59 |
BRKR 1.43 |
NVCR 0.00 |
PHG -1.00 |
ABT -1.00 |
SYK -1.00 |
Quick Ratio | -1.00 | 18/20 | INSP 169.57 |
GMED 125.00 |
BSX 87.14 |
NUVA 73.28 |
STE 49.51 |
SYK 49.12 |
PODD 46.59 |
ITGR 40.57 |
ABT 39.25 |
ZBH 29.66 |
MDT 27.31 |
BRKR 25.68 |
CNMD 14.66 |
EW 10.75 |
PHG -1.00 |
GKOS -1.00 |
NVCR -1.00 |
BIO -1.00 |
NARI -1.00 |
ZIMV -1.00 |
Long Term Debt to Equity | 0.00 | 17/20 | BRKR} 1.24 |
PODD} 1.21 |
CNMD} 1.01 |
ITGR} 0.71 |
NUVA} 0.61 |
ZIMV} 0.54 |
MDT} 0.51 |
BSX} 0.45 |
ZBH} 0.37 |
STE} 0.35 |
GKOS} 0.24 |
BIO} 0.16 |
GMED} 0.13 |
EW} 0.07 |
NARI} 0.07 |
INSP} 0.04 |
PHG} 0.00 |
SYK} 0.00 |
NVCR} 0.00 |
ABT} -1.00 |
Debt to Equity | 0.00 | 19/20 | BRKR 1.26 |
PODD 1.25 |
NUVA 1.02 |
CNMD 1.01 |
ITGR 0.72 |
MDT 0.58 |
ZIMV 0.54 |
BSX 0.53 |
ZBH 0.43 |
STE 0.36 |
SYK 0.28 |
GKOS 0.24 |
NVCR 0.24 |
BIO 0.16 |
GMED 0.13 |
NARI 0.08 |
EW 0.07 |
INSP 0.04 |
PHG 0.00 |
ABT -1.00 |
Burn Rate | -9.08 | 18/20 | BSX 7.96 |
ZIMV 4.66 |
GKOS 3.62 |
BRKR 2.56 |
ITGR 2.48 |
MDT 2.16 |
NARI 2.06 |
SYK 1.46 |
NUVA 0.77 |
ABT 0.00 |
NVCR 0.00 |
BIO -0.68 |
ZBH -1.00 |
EW -1.21 |
CNMD -3.43 |
STE -4.48 |
INSP -8.45 |
PHG -9.08 |
GMED -22.13 |
PODD -70.80 |
Cash to Cap | 0.08 | 2/20 | ZIMV 0.18 |
PHG 0.08 |
EW 0.08 |
PODD 0.05 |
GMED 0.05 |
BIO 0.05 |
NUVA 0.04 |
ZBH 0.03 |
INSP 0.03 |
BSX 0.02 |
SYK 0.02 |
BRKR 0.02 |
CNMD 0.02 |
MDT 0.01 |
GKOS 0.01 |
STE 0.01 |
ITGR 0.01 |
NARI 0.01 |
ABT 0.00 |
NVCR 0.00 |
CCR | 1.51 | 4/20 | ITGR 3.72 |
GMED 3.12 |
INSP 2.39 |
PHG 1.51 |
STE 0.99 |
PODD 0.98 |
CNMD 0.98 |
GKOS 0.52 |
MDT 0.44 |
BIO 0.38 |
BRKR 0.14 |
EW 0.10 |
NARI 0.05 |
NVCR 0.01 |
ABT 0.00 |
NUVA -0.07 |
ZIMV -1.04 |
BSX -2442.82 |
ZBH |
SYK |
EV to EBITDA | 77.29 | 10/20 | INSP} 382.86 |
SYK} 267.72 |
GMED} 236.00 |
PODD} 228.20 |
BSX} 219.91 |
ABT} 116.66 |
STE} 108.00 |
EW} 103.65 |
ITGR} 98.99 |
PHG} 77.29 |
NUVA} 47.54 |
CNMD} 43.12 |
BIO} 6.87 |
ZBH} -1.00 |
NVCR} -74.74 |
BRKR} -129.77 |
ZIMV} -168.88 |
GKOS} -323.48 |
NARI} -647.99 |
MDT} -4237.33 |
EV to Revenue | 1.37 | 17/20 | GKOS 22.14 |
PODD 11.09 |
BSX 10.32 |
NARI 8.13 |
INSP 7.25 |
EW 7.11 |
SYK 6.88 |
ABT 5.49 |
GMED 4.58 |
MDT 4.37 |
STE 4.37 |
NVCR 4.15 |
BRKR 3.08 |
ITGR 2.86 |
NUVA 2.37 |
CNMD 2.20 |
PHG 1.37 |
ZIMV 1.14 |
BIO 0.00 |
ZBH -1.00 |